There are two glucagon-like peptide-1 (GLP-1) receptor agonists that have been approved for the treatment of obesity in the United States: semaglutide and liraglutide. Both of these medications are injectable. The brand names for semaglutide include: Ozempic, Rybelsus, and Wegovy. The brand names for liraglutide include: Saxenda and Victoza.